Absci Corporation

Absci Corporation is a clinical-stage biopharmaceutical company focused on discovering and designing protein-based therapeutics using generative artificial intelligence and synthetic biology. Absci integrates AI-driven modeling with high-throughput wet lab capabilities to create antibody and other biologic candidates for complex disease areas. Its current pipeline spans programs in immunology, oncology, inflammatory disease, and dermatology, reflecting a platform approach to drug creation rather than a single-product model. The company also collaborates with pharmaceutical and biotechnology partners to support therapeutic discovery and development efforts. Headquartered in Vancouver, Washington, Absci plays a role in the growing market for AI-enabled drug discovery, where data science and biological engineering are combined to improve how new medicines are identified and optimized.